Production and Quality Assurance of Human Polyclonal Hyperimmune Immunoglobulins Against SARS-CoV-2.

Antibodies COVID-19 / therapy Humans Immunization, Passive Pandemics SARS-CoV-2 COVID-19 Serotherapy
COVID-19 Convalescent plasma Human hyperimmune immunoglobulins Passive immunotherapy SARS-CoV-2

Journal

Transfusion medicine reviews
ISSN: 1532-9496
Titre abrégé: Transfus Med Rev
Pays: United States
ID NLM: 8709027

Informations de publication

Date de publication:
07 2022
Historique:
received: 28 04 2022
revised: 01 06 2022
accepted: 02 06 2022
pubmed: 26 7 2022
medline: 14 9 2022
entrez: 25 7 2022
Statut: ppublish

Résumé

The coronavirus disease 2019 (COVID-19) pandemic has highlighted the potential therapeutic value of early passive polyclonal immunotherapy using high-titer convalescent plasma (CCP). Human polyclonal hyperimmune immunoglobulin (HIG) has several advantages over CCP. Unlike CCP, HIG can provide standardized and controlled antibody content. It is also subjected to robust pathogen reduction rendering it virally safe and is purified by technologies demonstrated to preserve immunoglobulin neutralization capacity and Fc fragment integrity. This document provides an overview of current practices and guidance for the collection and testing of plasma rich in antibodies against Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) and its industrial fractionation for the manufacture of quality-assured and safe HIG. Considerations are also given to the production of HIG preparations in low- and middle-income countries.

Identifiants

DOI: 10.1016/j.tmrv.2022.06.001 PMID: 35879213 PMC: PMC9183240
pubmed: 35879213
pii: S0887-7963(22)00021-9
doi: 10.1016/j.tmrv.2022.06.001
pmc: PMC9183240
pii:
doi:

Substances chimiques

Antibodies 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

125-132

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Références

EClinicalMedicine. 2021 Jun;36:100926
pubmed: 34109306
Cell. 2021 Apr 1;184(7):1804-1820.e16
pubmed: 33691139
Nature. 2020 Aug;584(7821):450-456
pubmed: 32698192
Transfusion. 2015 Jan;55(1):199-204
pubmed: 25066014
Lancet. 2021 Mar 6;397(10277):881-891
pubmed: 33617777
mBio. 2021 Apr 20;12(2):
pubmed: 33879585
Am J Hematol. 2000 Sep;65(1):30-4
pubmed: 10936860
Nat Med. 2021 Nov;27(11):2032-2040
pubmed: 34588689
Mayo Clin Proc. 2020 Sep;95(9):1888-1897
pubmed: 32861333
Vox Sang. 2022 Jun;117(6):789-795
pubmed: 35262936
Vox Sang. 2010 Jan;98(1):12-28
pubmed: 19660029
N Engl J Med. 2021 Nov 18;385(21):1951-1960
pubmed: 34407339
J Clin Invest. 2020 Jun 1;130(6):2757-2765
pubmed: 32254064
Nat Med. 2020 Nov;26(11):1708-1713
pubmed: 32934372
PLoS Med. 2021 Dec 20;18(12):e1003872
pubmed: 34928960
Blood. 2020 Nov 26;136(22):2588-2591
pubmed: 33001206
Clin Microbiol Rev. 2022 Sep 21;35(3):e0020021
pubmed: 35262370
J Lab Clin Med. 1980 Aug;96(2):334-46
pubmed: 6447181
JAMA. 2021 Nov 02;326(17):1690-1702
pubmed: 34606578
PLoS Negl Trop Dis. 2015 Feb 26;9(2):e0003501
pubmed: 25719558
Open Forum Infect Dis. 2021 Apr 30;8(6):ofab220
pubmed: 34136587
Vox Sang. 2021 Nov;116(10):1076-1083
pubmed: 33835489
N Engl J Med. 2022 May 5;386(18):1700-1711
pubmed: 35353960
J Med Virol. 2021 May;93(5):2890-2898
pubmed: 33386772
Lancet Microbe. 2021 May;2(5):e171-e172
pubmed: 33778791
Nat Med. 2021 Apr;27(4):622-625
pubmed: 33654292
JAMA. 2021 Apr 13;325(14):1467-1469
pubmed: 33646292
J Infect Dis. 2021 Nov 22;224(10):1707-1711
pubmed: 34543421
PLoS One. 2021 Mar 4;16(3):e0247640
pubmed: 33661923
Nature. 2020 Aug;584(7821):353-363
pubmed: 32659783
Nat Med. 2020 Jun;26(6):845-848
pubmed: 32350462
Transfusion. 2020 Dec;60(12):2938-2951
pubmed: 32935877
Transfus Med Rev. 2007 Apr;21(2):101-17
pubmed: 17397761
Nat Microbiol. 2020 Dec;5(12):1598-1607
pubmed: 33106674
Transfusion. 2021 Jun;61(6):1705-1709
pubmed: 33715160
Lancet. 2022 Feb 5;399(10324):497-499
pubmed: 35093207
Blood Transfus. 2021 Nov;19(6):467-478
pubmed: 34369872
Lancet. 2021 May 29;397(10289):2049-2059
pubmed: 34000257
N Engl J Med. 2021 Jul 1;385(1):90-92
pubmed: 33852796
Immunotherapy. 2021 Apr;13(5):397-407
pubmed: 33557591
Blood Rev. 2000 Jun;14(2):94-110
pubmed: 11012252
JAMA. 2020 Apr 28;323(16):1582-1589
pubmed: 32219428
Transfus Med Rev. 2003 Oct;17(4):241-51
pubmed: 14571392
N Engl J Med. 2021 Mar 18;384(11):1015-1027
pubmed: 33523609
J Clin Invest. 2020 Dec 1;130(12):6728-6738
pubmed: 32910806
Cochrane Database Syst Rev. 2021 May 20;5:CD013600
pubmed: 34013969
Cell. 2021 Nov 11;184(23):5699-5714.e11
pubmed: 34735795
Lancet. 2021 Apr 10;397(10282):1347-1348
pubmed: 33770519
Science. 2022 Jan 07;375(6576):43-50
pubmed: 34812653
Lancet. 2022 Feb 5;399(10324):530-540
pubmed: 35093205
N Engl J Med. 2021 Jun 10;384(23):2259-2261
pubmed: 33822494
Transfusion. 2021 Apr;61(4):1141-1147
pubmed: 33615484
Cell Host Microbe. 2022 Jan 12;30(1):97-109.e5
pubmed: 34953513
Cell Rep Med. 2021 Jun 15;2(6):100290
pubmed: 33969322
Transfusion. 2012 Oct;52(10):2113-21
pubmed: 22448967
Vox Sang. 2012 Jan;102(1):40-6
pubmed: 21545600
Transfusion. 2021 Jul;61(7):2099-2106
pubmed: 33829513
Transfusion. 2017 Dec;57(12):3019-3025
pubmed: 28880361
Nat Med. 2021 Nov;27(11):2012-2024
pubmed: 34504336
Transfusion. 2021 Oct;61(10):2837-2843
pubmed: 34342366
JAMA Oncol. 2021 Jun 17;:
pubmed: 34137799
Cell Rep. 2021 Mar 2;34(9):108790
pubmed: 33596407
Cell Rep Med. 2021 Apr 20;2(4):100255
pubmed: 33842902
J Clin Invest. 2020 Nov 2;130(11):6141-6150
pubmed: 32764200
Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9490-9496
pubmed: 32253318
Vox Sang. 2021 Sep;116(8):930-931
pubmed: 33745163
BioDrugs. 2017 Jun;31(3):251-261
pubmed: 28508264
Cell Rep Med. 2020 Oct 20;1(7):100126
pubmed: 33015650
Clin Rheumatol. 2020 Feb;39(2):541-546
pubmed: 31760541
Vox Sang. 2021 Jan;116(1):18-35
pubmed: 32533868
BioDrugs. 2016 Oct;30(5):441-451
pubmed: 27646589
J Clin Immunol. 1993 Jul;13(4):272-8
pubmed: 8227286
Cell. 2020 Sep 3;182(5):1284-1294.e9
pubmed: 32730807
Cell Rep. 2022 Feb 15;38(7):110368
pubmed: 35123652
Transfus Apher Sci. 2021 Feb;60(1):102957
pubmed: 32972861
Emerg Infect Dis. 2020 Jul;26(7):1478-1488
pubmed: 32267220
Biologicals. 2014 Sep;42(5):260-70
pubmed: 25096922
Immunity. 2021 Sep 14;54(9):2143-2158.e15
pubmed: 34453881
Transfus Med Rev. 2020 Jul;34(3):141-144
pubmed: 32359789
Kidney Int. 2021 Sep;100(3):702-704
pubmed: 34216675
N Engl J Med. 2021 Feb 18;384(7):610-618
pubmed: 33406353
J Infect Dis. 2021 Mar 29;223(6):957-970
pubmed: 33367897
Vaccines (Basel). 2021 Aug 18;9(8):
pubmed: 34452043
Lancet Microbe. 2022 Feb;3(2):e81-e82
pubmed: 34901897

Auteurs

Thierry Burnouf (T)

College of Biomedical Engineering, Graduate Institute of Biomedical Materials and Tissue Engineering, Taipei Medical University, Taipei, Taiwan; International PhD Program in Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan. Electronic address: thburnouf@gmail.com.

Birgit Gathof (B)

Department of Transfusion Medicine, University Hospital of Cologne, Köln, Germany. Electronic address: Birgit.Gathof@uk-koeln.de.

Evan M Bloch (EM)

Division of Transfusion Medicine, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Renée Bazin (R)

Héma-Québec, Medical Affairs and Innovation, Québec, Canada.

Vincenzo de Angelis (V)

National Blood Centre, Italian National Institute of Health, Rome, Italy.

Gopal Kumar Patidar (GK)

Department of Transfusion Medicine, All India Institute of Medical Sciences, New Delhi, India.

Rada M Grubovic Rastvorceva (RMG)

Institute for Transfusion Medicine of RNM, Skopje, North Macedonia; Faculty of Medical Sciences, University Goce Delcev, Štip, North Macedonia.

Adaeze Oreh (A)

Department of Planning, Research and Statistics, National Blood Service Commission, Federal Ministry of Health, Abuja, Nigeria.

Ruchika Goel (R)

Division of Transfusion Medicine, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Division of Hematology/Oncology, Simmons Cancer Institute at SIU School of Medicine and ImpactLife Blood Center, Springfield, IL, USA.

Naomi Rahimi-Levene (N)

Blood Bank, Shamir Medical Center, Assaf Harofeh MC, Zerifin, Israel.

Salwa Hindawi (S)

Haematology Department, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.

Arwa Z Al-Riyami (AZ)

Department of Hematology, Sultan Qaboos University Hospital, Muscat, Sultanate of Oman.

Cynthia So-Osman (C)

Department of Haematology, Erasmus Medical Centre, Rotterdam, The Netherlands; Unit Transfusion Medicine, Sanquin Blood Supply Foundation, Amsterdam, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Production and Quality Assurance of Human...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Infections de l'appareil respiratoire › Pneumopathie infectieuse › Pneumopathie virale › COVID-19 › Production and Quality Assurance of Human...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Production and Quality Assurance of Human...
questionsmedicales.fr › Techniques d'investigation › Techniques immunologiques › Immunisation passive › Production and Quality Assurance of Human...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Épidémies de maladies › Épidémies › Pandémies › Production and Quality Assurance of Human...
questionsmedicales.fr › Virus › Virus à ARN › Virus à ARN à brin positif › Nidovirales › Coronaviridae › Coronavirus › Betacoronavirus › Virus du SRAS › SARS-CoV-2 › Production and Quality Assurance of Human...
questionsmedicales.fr › Techniques d'investigation › Techniques immunologiques › Immunisation passive › Transfert adoptif › Sérothérapie COVID-19 › Production and Quality Assurance of Human...